There is growing optimism about Remdesivir, a repurposed drug (tried for hepatitis C and Ebola treatment) to treat COVID-19 patients. The drug is structurally similar to a component of the COVID-19 viral RNA. Therefore, drug is predicted to inhibit the viral multiplication in cells of the patients. Further, the drug is shown to reduce the production of inflammatory proteins by cells. Together, these observations support the notion that Remdesivir could be beneficial in COVID-19 patients. Correspondingly, in a clinical trial, which involved 113 COVID-19 patients, treatment with the drug resulted in a speedy recovery of the patients (and only 2 patients died). However, the clinical trial did not include a control group (patients without the drug). Therefore, additional clinical trials involving the drug are in progress to investigate its usefulness in treating COVID-19 patients.
Article Antiviral therapy in management of COVID-19: a systematic re...
Remdesivir for COVID-19: challenges of underpowered studies
John David Norrie. Published:April 29, 2020DOI:https://doi.org/10.1016/S0140-6736(20)31023-0
https://www.statnews.com/2020/04/23/data-on-gileads-remdesivir-released-by-accident-show-no-benefit-for-coronavirus-patients/
Dear Manash
Chinese publications are so unreliable that we cannot take them under serious consideration. To this we have to add that WHO made up of a bunch of corrupt and ignorant burócrats, did not publish the Chinese paper by accident. They did it on purpose. All this seems just part of the chinese-WHO conspiracy.
We have to wait until results of western studies are performed with the drug. China and WHO are unable to give an objective opinion.
- Badges
- Science topic
- Similar topics
- Chemistry
- Pharmacology
- Pharmaceuticals
- Drugs